Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry.

Fiche publication

Date publication

août 2023

Journal

Rheumatology (Oxford, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr TOUSSIROT Eric

Tous les auteurs :
Faganello D, Bertrand A, Meunier P, Avouac J, Toussirot E, Coury F, Seror R, Le Mélédo G, Germain V, Dellal A, Shima D, Hulin C, Prati C, Schaeverbeke T, Richez C, Truchetet ME, Kostine M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37540112

Résumé

Monoclonal Gammopathy of Undetermined Significance (MGUS) is common but there are scarce data regarding the effect of disease-modifying antirheumatic drugs (DMARDs) on this pre-malignant condition. We aimed to evaluate the impact of JAK inhibitors (JAKi) on MGUS when initiated for an active rheumatic disease.